Tamoxifen and Ovarian Function

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Berliere, Martine ^a   Duhoux, Francois P ^a   Dalenc, Florence ^b   Baurain, Jean Francois ^a   Dellevigne, Laurence ^a   Galant, Christine ^a   Van Maanen, Aline ^a   Piette, Philippe ^a   Machiels, Jean Pascal ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTRADIOL; ESTROGEN; FLUOROURACIL; FOLLITROPIN; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MULTIPLE CYCLE TREATMENT; OLIGOMENORRHEA; OVARY FUNCTION; PREMENOPAUSE; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AMENORRHEA; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE; MIDDLE AGED; OVARY; PREMENOPAUSE; RETROSPECTIVE STUDIES; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84879519721     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066616     Document Type: Article

References (26)

1. Rafdim PM, Fritz NF, Tormey DC, Jordan VC, (1988) Endocrine status of premenopausal node negative breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 48: 1026-9.
2. Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A, (2005) Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol; 23 (8): 1736-50.
3. Gonzalez Martin A, de la Cruz S, Marquez R, (2010) Adjuvant endocrine therapy in premenopausal women with breast cancer. Breast Cancer Res. Treat. 10: 1045-52.
4. Early Breast Cancer Trialists'Collaborative Group (1992) Systematic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(1): 71-85.
5. Early Breast Cancer Trialists'Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472): 1687-1717.
6. International Breast Cancer Study Group (2006) Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node positive breast cancer: international breast cancer study group trial 13-93. J Clin Oncol 24: 1332-41.
7. Ortman O, Pagani O, Jones A, Mass N, Noss D, et al. (2011) Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel. Cancer Treatment Reviews; 97-104.
8. Guidelines of the NCCN (2011) Definition of menopause. Available: http://www.nccn.org/professionnels/physicians/pdf/breast.pdf.
9. Burger HG, Hale GE, Robertson DM, Dennerstein L, (2007) A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. Hum Reprod Update 13: 559-565.
10. Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, et al. (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369(9574): 1711-1723.
11. Walshe JM, Denduluri N, Swain SM, (2006) Amenorrhea in premenopausal women for breast cancer. J Clin Oncol 24: 5769-79.
12. Ganz PA, Land SR, Geyer CE, Cecchini RS, Costantino JP, et al. (2011) Menstrual history and quality of life outcomes in women with node positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol (jco.ascopubs.org/content/29/9/1110.long).
13. Petrek JA, Naughton MJ, Caze LD, Paskett ED, Naftalis EZ, et al. (2006) Incidence, time course and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24: 1045-51.
14. Shapiro CL, Recht A, (2001) Side effect of adjuvant treatment of breast cancer. New Engl J Med 344: 1997-2008.
15. Manni A, Pearson OH, (1980) Antiestrogen induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep 64: 779-85.
16. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC, (1991) Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single-agent. J Natl Cancer in Inst 83: 1488-91.
17. Jordan VC, Fritz NF, Tormey DC, (1987) Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res 47: 624-30.
18. Mourits MJ, Devries EG, Ten Hoor KA, Van der Zee AGJ, Willemse PHB, (2007) Beware of amenorrhea during tamoxifen: it may be a wolf in sheep's clothing. J Clin Oncol 25: 3787-8.
19. Speroff L, Glass RH, Kase NG (1999) Clinical gynaecologic endocrinology and infertility. Ed. Philadelphia PA, Lippincott, Williams and Wilkins.
20. Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson A, (2003) Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by an anti-Müllerian hormone, inhibin-B and ovarian ultrasound. Hum Reprod 18: 2368-74.
21. Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, et al. (2010) Anti-mullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 116(3): 592-9.
22. Sakurai K, Enomoto K, Amano S, (2011) Recovery of menstruation after long-term chemotherapy and endocrine therapy in pre-menopausal patients with breast cancer. J Cancer Res Chim Oncol 137(4): 615-20.
23. Ahmad A, Shahabuddin S, Sheikh S, Kale P, Krishnappa M, et al. (2010) Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin Pharmacol Ther; 86 (6): 814-7.
24. Geutz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flushes. J Clin Oncol 23: 9312-8.
25. Singh MS, Francis PA, Michael M, (2005) Tamoxifen, cytochrome P450 genes and breast cancer clinical outocomes. Breast 20(2): 111-8.
26. Stebbing J, Stearn SV, Davidson NE, (2007) Role of CYP2D6 testing in selection of endocrine therapy for breast cancer. Pharmacogenomics 8: 1-3.